{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:41:21Z","timestamp":1783532481307,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004846","name":"Beijing University of Chinese Medicine","doi-asserted-by":"publisher","award":["zyyzdxk\u20142023268"],"award-info":[{"award-number":["zyyzdxk\u20142023268"]}],"id":[{"id":"10.13039\/501100004846","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-025-02804-4","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:51:34Z","timestamp":1747389094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7861-8041","authenticated-orcid":false,"given":"Xiaohua","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2804_CR1","doi-asserted-by":"publisher","unstructured":"Chen Q, Zhang M, Zheng S, Tong Y, Tan Y. Therapeutic progress in relapsed\/refractory multiple myeloma. Ann Hematol 2024;103(6):1833\u20131841. (In eng). https:\/\/doi.org\/10.1007\/s00277-024-05730-y.","DOI":"10.1007\/s00277-024-05730-y"},{"issue":"1","key":"2804_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","volume":"9","author":"L Sanchez","year":"2016","unstructured":"Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):51. https:\/\/doi.org\/10.1186\/s13045-016-0283-0.","journal-title":"J Hematol Oncol"},{"issue":"14","key":"2804_CR3","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1002\/cncr.32065","volume":"125","author":"AK Nooka","year":"2019","unstructured":"Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma. Cancer. 2019;125(14):2364\u201382.","journal-title":"Cancer"},{"issue":"5","key":"2804_CR4","doi-asserted-by":"publisher","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","volume":"18","author":"A Gozzetti","year":"2022","unstructured":"Gozzetti A, Ciofini S, Simoncelli M, et al. Anti CD38 monoclonal antibodies for multiple myeloma treatment. Hum Vaccin Immunother. 2022;18(5):2052658. https:\/\/doi.org\/10.1080\/21645515.2022.2052658.","journal-title":"Hum Vaccin Immunother"},{"key":"2804_CR5","unstructured":"NCCN Clinical Practice Guidelines in Oncology: multiple myeloma (Version 3.2023). (https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf)."},{"issue":"3","key":"2804_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology\u202f: official journal of the European Society for Medical Oncology. 2021;32(3):309\u201322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"Supplement 1","key":"2804_CR7","doi-asserted-by":"publisher","first-page":"7278","DOI":"10.1182\/blood-2022-162339","volume":"140","author":"A Chari","year":"2022","unstructured":"Chari A, Kaufman JL, Laubach JP, et al. Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups. Blood. 2022;140(Supplement 1):7278\u201381. https:\/\/doi.org\/10.1182\/blood-2022-162339.","journal-title":"Blood"},{"issue":"10218","key":"2804_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/s0140-6736(19)32956-3","volume":"395","author":"M-V Mateos","year":"2020","unstructured":"Mateos M-V, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132\u201341. https:\/\/doi.org\/10.1016\/s0140-6736(19)32956-3.","journal-title":"Lancet"},{"key":"2804_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bjh.18718","volume":"201","author":"S Basu","year":"2023","unstructured":"Basu S, Kumar SK, Moreau P, et al. Daratumumab plus Lenalidomide\/ dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA update. Br J Haematol. 2023;201:17\u20138. https:\/\/doi.org\/10.1111\/bjh.18718.","journal-title":"Br J Haematol"},{"key":"2804_CR10","unstructured":"Hematologists Society of Chinese Medical Doctor Association HSoCMA. Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision). Zhonghua nei ke za zhi 2022;61(5)."},{"key":"2804_CR11","unstructured":"Clinical Practice Guideline-MULTIPLE MYELOM. (https:\/\/myeloma.org.au\/wp-content\/uploads\/2022\/09\/MSAG_Myeloma-Clinical-Practice-Guideline-2022_Final-1.pdf)."},{"key":"2804_CR12","unstructured":"Chaimani. A, Caldwell. DM, Li. T, Higgins. JP, Salanti. G. Undertaking network meta-analyses. In: JPT. H, J. T, J. C, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024): Cochrane; 2024."},{"issue":"11","key":"2804_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"key":"2804_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16.","journal-title":"Trials"},{"key":"2804_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"3","key":"2804_CR16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/bimj.201800167","volume":"62","author":"G R\u00fccker","year":"2020","unstructured":"R\u00fccker G, Petropoulou M, Schwarzer G. Network meta-analysis of multicomponent interventions. Biometrical journal Biometrische Zeitschrift. 2020;62(3):808\u201321. https:\/\/doi.org\/10.1002\/bimj.201800167.","journal-title":"Biometrical journal Biometrische Zeitschrift"},{"key":"2804_CR17","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2019013","volume":"41","author":"SR Shim","year":"2019","unstructured":"Shim SR, Kim S-J, Lee J, R\u00fccker G. Network meta-analysis: application and practice using R software. Epidemiology and health. 2019;41: e2019013. https:\/\/doi.org\/10.4178\/epih.e2019013.","journal-title":"Epidemiology and health"},{"issue":"2","key":"2804_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/bimj.201900339","volume":"63","author":"G R\u00fccker","year":"2021","unstructured":"R\u00fccker G, Schmitz S, Schwarzer G. Component network meta-analysis compared to a matching method in a disconnected network: A case study. Biom J. 2021;63(2):447\u201361.","journal-title":"Biom J"},{"key":"2804_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58. https:\/\/doi.org\/10.1186\/s12874-015-0060-8.","journal-title":"BMC Med Res Methodol"},{"issue":"20","key":"2804_CR20","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","volume":"25","author":"RM Harbord","year":"2006","unstructured":"Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443\u201357. https:\/\/doi.org\/10.1002\/sim.2380.","journal-title":"Stat Med"},{"issue":"10192","key":"2804_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1.","journal-title":"Lancet"},{"issue":"12","key":"2804_CR22","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","volume":"124","author":"MV Mateos","year":"2014","unstructured":"Mateos MV, Oriol A, Mart\u00ednez-L\u00f3pez J, et al. GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood. 2014;124(12):1887\u201393. https:\/\/doi.org\/10.1182\/blood-2014-05-573733.","journal-title":"Blood"},{"issue":"21","key":"2804_CR23","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1182\/blood.v122.21.1966.1966","volume":"122","author":"R Niesvizky","year":"2013","unstructured":"Niesvizky R, Flinn I, Rifkin RM, et al. Efficacy and safety of three bortezomib-based induction and maintenance regimens in previously untreated, transplant-ineligible multiple myeloma (MM) patients (Pts): final results from the randomized, phase 3b, US community-based UPFRONT study (NCT00507416). Blood. 2013;122(21):1966. https:\/\/doi.org\/10.1182\/blood.v122.21.1966.1966.","journal-title":"Blood"},{"issue":"4","key":"2804_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313. https:\/\/doi.org\/10.1056\/NEJMoa2312054.","journal-title":"N Engl J Med"},{"issue":"10","key":"2804_CR25","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(20)30452-6.","journal-title":"Lancet Oncol"},{"issue":"10068","key":"2804_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s0140-6736(16)31594-x","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(16)31594-x.","journal-title":"Lancet"},{"issue":"26","key":"2804_CR27","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","volume":"116","author":"JA Zonder","year":"2010","unstructured":"Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010;116(26):5838\u201341. https:\/\/doi.org\/10.1182\/blood-2010-08-303487.","journal-title":"Blood"},{"issue":"6","key":"2804_CR28","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.clml.2023.02.009","volume":"23","author":"W Fu","year":"2023","unstructured":"Fu W, Bang S-M, Huang H, et al. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: the phase 3 OCTANS study. Clin Lymphoma Myeloma Leuk. 2023;23(6):446\u2013455.e4. https:\/\/doi.org\/10.1016\/j.clml.2023.02.009.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"2804_CR29","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375\u201382. https:\/\/doi.org\/10.1182\/blood-2011-11-395749.","journal-title":"Blood"},{"issue":"21","key":"2804_CR30","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","volume":"127","author":"P Moreau","year":"2016","unstructured":"Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127(21):2569\u201374. https:\/\/doi.org\/10.1182\/blood-2016-01-693580.","journal-title":"Blood"},{"key":"2804_CR31","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Paiva B, Cedena Romero MT, et al. GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus\/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years. Blood2023:209\u2013209.","DOI":"10.1182\/blood-2023-179866"},{"key":"2804_CR32","doi-asserted-by":"crossref","unstructured":"Mollee P, Reynolds J, Janowski W, et al. A randomized study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) versus VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant-ineligible patients with multiple myeloma (AMaRC 03\u201316). Blood2021:2728\u20132728.","DOI":"10.1182\/blood-2021-152500"},{"issue":"10","key":"2804_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.597","volume":"19","author":"L Kumar","year":"2019","unstructured":"Kumar L, Chellapuram SK, Sahoo R, Gupta R. VRd versus VCd as induction therapy for newly diagnosed multiple myeloma: a phase III, randomized study. Clin Lymphoma Myeloma Leuk. 2019;19(10): e361. https:\/\/doi.org\/10.1016\/j.clml.2019.09.597.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"2804_CR34","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S2352-3026(23)00366-6","volume":"130","author":"A Mookerjee","year":"2017","unstructured":"Mookerjee A, Gupta R, Jasrotia S, et al. Bortezomib, lenalidomide and low-dose dexamethasone (VRD) versus lenalidomide and low-dose dexamethasone (Ld) for newly-diagnosed multiple myeloma- a randomized phase III study. Blood. 2017;130(Supplement 1):906\u2013906. https:\/\/doi.org\/10.1016\/S2352-3026(23)00366-6.","journal-title":"Blood"},{"issue":"2","key":"2804_CR35","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/S2352-3026(23)00366-6","volume":"11","author":"EK Mai","year":"2024","unstructured":"Mai EK, Goldschmid H, Miah K, et al. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. The Lancet Haematology. 2024;11(2):e101\u201313. https:\/\/doi.org\/10.1016\/S2352-3026(23)00366-6.","journal-title":"The Lancet Haematology"},{"issue":"10262","key":"2804_CR36","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet (London, England). 2020;396(10262):1563\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(20)32292-3.","journal-title":"Lancet (London, England)"},{"issue":"8","key":"2804_CR37","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Oriol A, Nahi H, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. Journal of clinical oncology\u202f: official journal of the American Society of Clinical Oncology. 2023;41(8):1590\u20139. https:\/\/doi.org\/10.1200\/JCO.22.00940.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"10245","key":"2804_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos M-V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet (London, England). 2020;396(10245):186\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(20)30734-0.","journal-title":"Lancet (London, England)"},{"issue":"6","key":"2804_CR39","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(21)00128-5.","journal-title":"Lancet Oncol"},{"key":"2804_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.critrevonc.2019.07.001","volume":"143","author":"L Sekine","year":"2019","unstructured":"Sekine L, Ziegelmann PK, Manica D, et al. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: a systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials. Crit Rev Oncol Hematol. 2019;143:102\u201316. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.001.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"2804_CR41","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1080\/10428194.2022.2038376","volume":"63","author":"J Wang","year":"2022","unstructured":"Wang J, Arroyo-Suarez R, Dasari S, Sekaran K, Tse W. Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX. CASTOR and MAIA Leukemia & lymphoma. 2022;63(7):1669\u201377. https:\/\/doi.org\/10.1080\/10428194.2022.2038376.","journal-title":"CASTOR and MAIA Leukemia & lymphoma"},{"key":"2804_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103211","volume":"159","author":"LL Chong","year":"2021","unstructured":"Chong LL, Soon YY, Soekojo CY, Ooi M, Chng WJ, de Mel S. Daratumumab-based induction therapy for multiple myeloma: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159: 103211. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103211.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2804_CR43","doi-asserted-by":"publisher","unstructured":"Langer P, John L, Monsef I, Scheid C, Piechotta V, Skoetz N. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant. Cochrane Database Syst Rev 2024;5(5):Cd013595. (In eng). https:\/\/doi.org\/10.1002\/14651858.CD013595.pub2.","DOI":"10.1002\/14651858.CD013595.pub2"},{"issue":"9","key":"2804_CR44","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/aje\/kwp014","volume":"169","author":"NJ Welton","year":"2009","unstructured":"Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol. 2009;169(9):1158\u201365. https:\/\/doi.org\/10.1093\/aje\/kwp014.","journal-title":"Am J Epidemiol"},{"key":"2804_CR45","doi-asserted-by":"publisher","unstructured":"Overdijk MB, Verploegen S, B\u00f6gels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs 2015;7(2):311--21. https:\/\/doi.org\/10.1080\/19420862.2015.1007813.","DOI":"10.1080\/19420862.2015.1007813"},{"issue":"3","key":"2804_CR46","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384\u201394. https:\/\/doi.org\/10.1182\/blood-2015-12-687749.","journal-title":"Blood"},{"issue":"2","key":"2804_CR47","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000350","volume":"4","author":"D Swan","year":"2020","unstructured":"Swan D, Gurney M, Krawczyk J, Ryan AE, O\u2019Dwyer M. Beyond DNA damage: exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma. Hemasphere. 2020;4(2): e350. https:\/\/doi.org\/10.1097\/hs9.0000000000000350.","journal-title":"Hemasphere"},{"key":"2804_CR48","doi-asserted-by":"publisher","unstructured":"Santos Ads, Santos HHdM, Salvino MA, et al. Immune Profiling Evaluation of newly diagnose multiple myeloma (NDMM) transplant eligible (TE) patients treated with daratumumab, cyclophosphamide, thalidomide and dexamethasone. Preliminary Results. Blood 2020;136:3\u20134. https:\/\/doi.org\/10.1182\/blood-2020-141438.","DOI":"10.1182\/blood-2020-141438"},{"issue":"1","key":"2804_CR49","doi-asserted-by":"publisher","first-page":"1859263","DOI":"10.1080\/2162402X.2020.1859263","volume":"10","author":"SD Naicker","year":"2021","unstructured":"Naicker SD, Feerick CL, Lynch K, et al. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. Oncoimmunology. 2021;10(1):1859263. https:\/\/doi.org\/10.1080\/2162402X.2020.1859263.","journal-title":"Oncoimmunology"},{"issue":"5","key":"2804_CR50","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1586\/14737140.2015.1033407","volume":"15","author":"Y Kim","year":"2015","unstructured":"Kim Y, Schmidt-Wolf IGH. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2015;15(5):491\u20137. https:\/\/doi.org\/10.1586\/14737140.2015.1033407.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"2804_CR51","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2010.030759","volume":"96","author":"MS van der Veer","year":"2011","unstructured":"van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96(2):284\u201390. https:\/\/doi.org\/10.3324\/haematol.2010.030759.","journal-title":"Haematologica"},{"key":"2804_CR52","doi-asserted-by":"publisher","unstructured":"Casneuf T, Adams rHC, van de Donk NWCJ, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia 2021;35(2):573--584. https:\/\/doi.org\/10.1038\/s41375-020-0855-4.","DOI":"10.1038\/s41375-020-0855-4"},{"issue":"5","key":"2804_CR53","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00262-022-03322-1","volume":"72","author":"JL Thangaraj","year":"2023","unstructured":"Thangaraj JL, Jung SH, Vo MC, et al. Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model. Cancer Immunol Immunother. 2023;72(5):1233\u201346. https:\/\/doi.org\/10.1007\/s00262-022-03322-1.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02804-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-02804-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02804-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:51:38Z","timestamp":1747389098000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-025-02804-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2804"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-02804-4","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}